Skip to content
Menu

Baird Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $568

Benzinga Newsdesk 5 hours ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

Baird analyst Joel Beatty maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and raises the price target from $514 to $568.

Baird analyst Joel Beatty maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and raises the price target from $514 to $568.

Read at benzinga.com